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1.1 Brief History of Malaria 
Malaria has been present since time immemorial and remains one of the worlds most 
prevalent health problems. In the 4th century BC, the Greeks noted an association 
between people exposed to swamp lands and the subsequent development of fevers. The 
Romans later called this disease mal'aira (bad air), due to the foul smelling air near the 
swamps. It was only in the 1890s that parasite gametocytes were first observed in blood 
and it was postulated that they were transmitted by mosquitos. Pioneering work by Sir 
Ronald Ross established the main features of the parasitic life cycle, for which he received 
the Nobel Prize in 1902. During the 20th century, a number of advances were made 
towards understanding the parasite, developing antimalarial drugs and to controlling the 
mosquito vector (Prescott et a/., 1993). 
1.2 Prevalence of Malaria 
Although the geographical distribution of malaria has been reduced over the past 50 
years, 40% of the world's population is still affected by the disease (Figure 1.2.). 
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Figure 1.2. Global distribution of malaria from 1946- 1994 (Reproduced with permission from A. 
Mellinger, The Centre for International Development, Cambridge, Massachusetts) 
It is estimated that malaria is responsible for 300-500 million clinical cases and over 1 
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Figure 1.2.1. Distribution of malaria in South Africa, 1995 (Reproduced with permission from B. 
Sharp, National Research Programme, MRC, Durban, South Africa) 
1.3 Economic Burden of Malaria 
The economic and social burden of the disease has resulted in lower rates of economic 
growth in malaria endemic countries (Sachs and Malaney, 2002). Medical costs of 
prevention, treatment and care puts an additional strain on health systems, which usually 
have limited resources. A bout of malaria would result in a loss of at least 5 workdays for 
an individual, a loss of income for a family and reduced productivity for an employer. In 
the rural areas where farming is often the sole means of income, working days off result 
in a reduced harvest production. In school children, malaria leads to poor school 
attendance and impairment of learning. Women are at a higher risk of getting malaria 
during pregnancy than any other time. For pregnant women, malaria often causes 
anaemia, maternal death and is associated with a low birth weight among newborns. The 
prevalence of malaria in an area can lead to a decline in international trade and tourism 











There is a strong correlation between malaria, poverty and development, which is often 
underestimated (Sachs and Malaney, 2002). The cost to human and social wellbeing is 
large and is exacerbated in the poorer communities. 
1.4 Life cycle of the Malaria Parasite 
Malaria is caused by the protozoan parasite Plasmodium falciparum and is transmitted by 
the female Anopheles mosquito. The life cycle of the malaria parasite is complex and 
consists of four stages. Two asexual stages occur in the human host and one asexual and 
sexual stage take place in the mosquito vector (Figure 1.4.). 
Life Cycle of the Malarial 
Figure 1.4. Life cycle of the malaria parasite (Reproduced with permission from S. Sharma, The 
Institute of Fundamental Research, Bombay, India) 
When an infected mosquito bites an individual, a small amount of saliva containing an 
anticoagulant and sporozoites enters the bloodstream. Once in the bloodstream the 
sporozoites invade liver cells where they undergo asexual fission to produce merozoites. 
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Introduction: DlVg Discovery & Development 
Table 1.8. Criteria for determining if a compound is a hit, lead or pre-clinical candidate 
Hit Lead Pre-cllnical candidate 
In vitro activity ./ ./ ./ 
In vivo activity ./ ./ 
Structure-activity relationship trends ./ ./ 
Known mechanism of action ./ ./ 
Pharmacokinetic profile ./ ./ 
Acceptable estimated daily dose ./ 
Selectivity: related systems ./ ./ 
Selectivity: wide range systems ./ 
Acceptable Cyp450 profile ./ 
Physical properties: Mwt, logP ./ ./ 
Solubility ./ 
Chemically tractable ./ ./ 
Synthetic routes ./ ./ 
Clean in early toxicity (e.g. 7 day rat) ./ 
1.8.1 Drug discovery 
Drug discovery involves finding novel biologically active hits that give positive results in 
the initial screening process. Bioassay  relevant to the therapeutic targets are essential in 
the screening stage and provide important information to monitor the activity of the hits. 
In general the bioassays are in vitro tests against isolated sub-cellular systems, lower 
organisms or culture cells, which are usually quicker and less expensive than in vivo 
methods. Once a suitable bioassay has been identified, different types of chemical 
compounds can be screened for activity. Broadly speaking, four different approaches are 
used to discover new hit compounds. These are: empirical screening methods, rational 
drug deSign, drug metabolism studies and clinical observations. The empirical approach 
relies on screening large numbers of diverse drug-like compounds. The source of 
compounds could be synthetic chemical libraries, historical compound collections, 
combinatorial libraries or natural product libraries including plant, marine and microbial 
compounds (Harvey, 1999). With the empirical process, there is no attempt to design an 
active compound and the large number and variety of structures that the libraries offer 
increase the probability of getting a hit (Terret et aI., 1995). The other major source of 




















































































Plate 2. Photograph gallery of Harpagophytum procumbens 
c) Secondary tubers of H. procumbens 
e) Sliced and dried roots of 
H. procumbens 
b) Characteristic fruit of H. procumbens 
d) H. procumbens under cultivation at Grassroots 
f) Examples of H. procumbens 
products 
Photographs a,b,d,e and f reproduced with permission from van Wyk B.E, Medicinal Plants of South 
Africa and People's Plants. A Guide to Useful Plants of Southern Africa. Briza Publications, Pretoria. 
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spectrum of the main peak in the 56% ACN fraction (Appendix 2, A2.2) and in the 60% 
ACN fraction (Appendix 2, A2.3) were identical, showing absorption maxima at 
approximately 210nm and 280nm. Furthermore, the UV spectra across the main peaks 
were uniform, suggesting a single compound within the peak. Since the fractions eluted 
with 56% ACN and 60% ACN were found to be greater than 80% pure, they were not 
subjected to further fractionation and will be referred to as compounds 56 and 60 
respectively. 
~S~D~at~a~1:~56~-~26~.~DO~1 __ ~Da~t~a2~: __________ ~At~t~en~:~ll~ ______________ -, 
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The other SPE fractions produced between 56% and 60% ACN showed moderate activity, 
and HPLC analysis indicated that these fractions contained tailing amounts of compounds 
56 and 60 (Chapter 7, 7.4.1). Since 56 and 60 displayed the greatest antiplasmodial 
activity, they were focused on for further investigations. The yield of 56 was 
approximately 0.033% and of 60 it was 0.015% by weight of the powdered H 
procumbens roots. Of the 10 kgs of the powdered H procumbens roots acquired, several 
kilograms were exhaustively extracted with PE and purified by SPE to yield measurable 
amounts of compounds 56 and 60 for structure elucidation. 
4.2.3 Identification and characterisation of compounds 56 and 60 from 
H. procumbens 
The identity of 56 and 60 (Figure 4.2.3.) was determined by mass spectrometry 
(HREIMS), infrared spectroscopy, speCific rotation, melting point determination, lH, 13C, 
HSQC, HMBC, COSY and NOESY NMR experiments. The lH, 13C, HMBC, COSY and NOESY 
NMR results for 56 and 60 are summarised in Tables 4.2.3.2 and 4.2.3.3. For 
convenience purposes, the structure elUCidation discussion of the isolated compounds will 
follow their respective NMR data tables. Copies of the HREIMS, NMR and IR spectra are in 
Appendix 2 (A2.2 and A2.3). The molecular weight and formula, melting point, specific 
rotation and IR data for the isolated compounds are given in Table 4.2.3.4. 
OH 
19 18 19 18 
8,11,13-Totaratriene-12-13-diol (56) 8,11,13-Abietatrien-12-ol (60) 
Figure 4.2.3. Structures, numbering and stereochemistry of compounds 56 and 60 
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Activity of H. procumbens (batch III) and the active compounds 
-------- - --
compounds have been published, but no antiplasmodial properties have been 
documented, to the best of my knowledge. 
4.3.5 Reported abietane diterpenes with anti plasmodial activity 
Many of the abietane diterpenes extracted from natural sources have displayed intrinsic 
antimicrobial activity. A thorough literature search revealed that a single abietane-type 
ester, 3-0-benzoylhosloppone (Figure 4.3.5), as well as four tanshinones, including 
cryptotanshinone (Figure 4.3.5), with abietane-type skeletons have been shown to 





Figure 4.3.5. Compound 3-0-benzoylhosloppone, cryptotanshinone, 56 and 60 
The compound 3-0-benzoylhosloppone was isolated from a hexane extract of the root 
bark of the plant Holsundia opposita (Achenbach et aI., 1992). H. opposita is widely 
distributed in East and West Africa and is traditionally used to treat malaria (Achenbach et 
aI., 1992). The crude extract of the root bark was found to exhibit significant in vitro 
activity against P. falciparum, with an lCso value of 5.6f.lgmr1. Purification of the extract 
led to the isolation of 3-0-benzoylhosloppone, which showed in vitro activity against both 
a CQ-resistant strain Kl (ICso=0.40f.lQmr
1
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Figure 5.3.3.1. 
A Summary of the ICso values of the amines (2-6) against P. fa/ciparum DlD and Kl 
B Summary of the ICso values of compounds 56 and 60, totarol, and the ~-amino alcohols 
(2-6) against P. fa/ciparum DlD and Kl 
C Summary of the ICso values of compounds 56 and 60, totarol and the ~-amino alcohols 



















Cmpd 56 Cmpd 60 Totarol Cmpd 2 Cmpd3 Cmpd4 Cmpd 5 Cmpd 6 
Compounds 
Figure 5.3.3.2 Summary of the selective (51) and resistance indexes (R1) of the tested compounds 
5.3.4 In vitro anti plasmodial activity of compound 56 and 6 when 
combined with chloroquine 
When different antimalarial agents are taken simultan ously, they often interact in a 
specific way that can be classified as additive, synergistic or antagonistic. A technique 
adapted from Chawira and Warhurst (1987), using fixed ratios of predetermined 
concentrations needed to inhibit parasite growth by 50% (ICso) was used to determine 
the interaction of compound 56 with CQ, and compound 6 with CQ (Details in Chapter 7, 
7.6.1). Compound 6 was chosen as a representative of the synthesised ~-amino alcohols. 
Similarly, compound 56 served as an example of the unmodified phenolic diterpenes. The 
results are illustrated in Figure 5.3.4. 
Compound 56 - CO Compound 6 - CQ 
100.--------------; 100.------------, 





Cmpd 56 1.0 0.5 0.0 x ICso CC08 1.0 0 .5 0 .0 x ICso 
CO 0.0 0.5 1.0 x ICso CO 0 .0 0 .5 1.0 x ICso 
Figure 5.3.4. Additive effect shown by the compound 56 and CQ combination and by the 
ompound 6 and CQ combination on P. fa!ciparum D10. The 95% confidence intervals for the 











If the effect of the combination is additive, then the parasite viability values for the fixed 
ratios lie on the straight line joining the values obtained for the drugs individually. 
Synergism is indicated by points below the line, and antagonism by points above the line. 
Although the variability within the set of data was high (Le. the points did not lie on a 
straight line), the results indicate that a combination of CQ and compound 56 had an 
additive effect, as did the combination of compound 6 and CQ. 
5.3.5 Separation of the possible diastereoisomers in compound 3 
The duplication of a single pair of NMR resonances in compound 3 suggested that there 
may be a mixture of diastereoisomers. While enantiomers have identical physical 
properties, diastereoisomers have different physical properties and can usually be 
separated by techniques that utilise these. In an attempt to separate the possible 
diastereoisomers of 3, successive development TLC was used in addition to HPLC (Details 
in Chapter 7, 7.5). 
The TLC technique yielded a single spot after several developments. The HPLC profile of 
3 (Figure 5.3.5.) indicated that the compound was 86% pure and contained a minor 
impurity. 
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Materials and Methods 
- 65% ACN mobile phases were used as opposed to the 100ml volumes. The activity of 
the 200ml elution fractions was compared to that of the 100ml fractions (Figure 7.4.1.1). 
Water 13.77 





ti 70 III .. 1.83 
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75 ••••••••••••••••• 16.41 
80 _ ••• 3.81 
Acetone 6.87 
0 5 10 15 20 
ICso values ugmr' 
Figure 7.4.1. Summary of the lC50 values of the fractions eluted with 55-80% ACN, and the water 
and acetone washes. The values represent the mean IC50 value of two independent experiments 
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ICso values ugmr' 
Figure 7.4.1.1. Comparison of the lC50 values of the 55-65% ACN SPE fractions eluted with 
lOOmis and 200mls of mobile phase. The values represent the mean IC50 value of two independent 
experiments each performed in duplicate 
For the 100ml elution volumes the 60% and 61% ACN fractions were the most active, 
whereas for the 200m I samples the activity was observed in the 59% and 60% fractions. 
The HPLC retention time and UV absorbance of the prominent peak in the 60% ACN 











Similarly, the main constituent in the 61% ACN (lOOml) sample was identical to the major 
component in the 60% ACN (200ml) fraction. By doubling the elution volume the active 
compounds were eluted at a lower percentage of ACN and carry-over between SPE 
fractions was minimised. To further purify the active 59% and 60% ACN (200ml) 
fractions, additional 56% and 57% ACN washes were introduced to remove any unwanted 
material before the 59% ACN elution. The introduction of these two washes changed the 
HPLC profile of the 59% ACN fraction considerably. It was found that a 55% wash 
(200ml) followed by a 56% ACN (200ml), 59% ACN (200ml) and 60% ACN (200ml) 
elution resulted in a single prominent peak for the 56% ACN sample, two main peaks for 
the 59% ACN and a single prominent peak for the 60% ACN sample (Figure 7.4.1.2). By 
comparing the HPLC retention times and UV absorbance, the 59% ACN sample appeared 
to contain the main constituent in the 56% (56) and 60% (60) ACN fractions. This was 
confirmed by HREIMS analysis of the 59% ACN fraction, which showed that it contained 
the molecular ions of both 56 and 60. Furthermore, all three fractions displayed similar 
anti plasmodial activity. The introduction of additional 57% and 58% ACN mobile phases 
appeared to spread out 56 and 60 amongst the 57%, 58% and 59% ACN fractions. 
Thus, the final SPE purification procedure that provided optimum separation of the active 
components 56 and 60 conSisted of a C18 ISOLUTE cartridge and 200ml volumes of H20: 
ACN mobile phases in the ratio of 45: 55,44: 56,41: 59,40: 60,39: 61. Several grams of 
the PE extract were purified by SPE to obtain sufficient quantities of 56 and 60 for 
structure elucidation and in vitro testing. The HPLC profiles of SPE fractions from different 
runs confirmed that tile separation procedure was reproducible and that the level of 
purity was consistent. Scheme 7.4.1 illustrates the isolation and purification of the active 
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Scheme 7.4.1. SPE purification of the active compounds 56 and 60 from H. procumbens (batch 
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List of spectra: 
• HPLC profile 
• UV absorbance 
• IR 
• HREIMS 
• lH NMR (600MHz, C0300) 
• 13C NMR (600MHz, C0300) 
• HSQC (SOOMHz, C0300) 
• HMBC (SOOMHz, C0300) 
• COSY (SOOMHz, C0300) 
• NOESY (SOOMHz, C0300) 




































































- - -. .. 
I 






...j - - - - - -1- _____ _ _ 
I 




-- - - - - t- - - _. . ... ,- - - - - - 1- -
I 
_ _ I __ _ _ L -' . ___ _ __ I _ 




















































El ... J 































'" ' o 
r--
Appendix 2 
------~~;:::::=:~LL ·9Z9 ~ 
<0 























J f I ' I I I I I " I I I t II I I , , I I I I I I I t II I I I I I I I • , I 1 I I I f I I I I I I I I I I I I I I I I I I I I I I I , r- 8 
LO 0 LO 0 LO 0 LO 0 LO 0 LO 0 LO 0 '<t 
ID ID LO LO '<t '<t ("') ("') N N 
a::>uen!WsueJl% 
189 
University of Cape Town
SCAN GRAPH. Flagging=High Resolution M/z. Filter=[lntO.4%. Range:0-330. Excl: Ref/Ex.].Highlighting=Base Peak. 




























, , , 








o JI 'I 1"1111111 11111111" ,iIll'"" 111111111.1111111111/1 ,111"1"1I1111'111/1111"11I111/llljlllllIlllIllll'llllllll"II/111111111)11'\11111,111 '1 1,11""1 1 1 1,\1""," ,1.l1)l1\.1 \., liljlll, 111111,11, 1,"1)11111, ,dllllll" 
50 1 00 150 200 250 300 
High Resolution M/z 











1 1 ,-, , , I r , , , I 1 I I , I ' I I I I ' , IT 
6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 
-\0 - Figure A2.2.5 lH NMR spectrum of 56 in CD30D, 600MHz 



















120 110 100 90 
















































































































. '!J.G'! . 
. t,-. *' . ..' 
.'() ".t"· 











































































10 9 8 
















University of Cape Town
F2 
(pp.m) 
0 . 5 





















¥ I ,'--'---T-'-T--r 
3.5 3.0 2 . 5 2.0 1.5 1.0 0 5 
F 1 (ppm) 






















~ o o 
U) 
197 
















a (Ql 0 
GD IDJ po 
" ~. [ [-' 'T 
3.5 3.0 2.5 2.0 1.5 1.0 0.5 
Fl (ppm) 





















List of spectra: 
• H PLC profi Ie 
• UV absorbance 
• IR 
• HREIMS 
• lH NMR (400MHz, CDCh) 
• 13C NMR (400MHz, COCh) 
• HSQC (300M Hz, COCI3) 
• HMBC (300M Hz, COCI3) 
• COSY (SOOMHz, CDCI3) 
• NOESY (SOOMHz, COCI3) 



































































I I I 
.- - - i" - -- - - - I - -- - - - - t - - - _. 
I 
- -- - - '-1 .- - _ •• - .- - J - - .- - -. - - - - - - -." .-


























o ~~ 00-o 0 _ 





























































k=====-------=:=::::::===---=g ~ "OV L 
I I I I J' I I'" • " I I , I I I 
o LO 0 LO 




























o LO 0 LO 0 LO 0 LO 0 LO 0 LO ~ 
















University of Cape Town
SCAN GRAPH. Flagging=High Resolution M/z. Filter=[lntO.4%. Excl: ReflEx.].Highlighting=Base Peak. 














































o 11 II 11.11111"11 ,,111111111,.111111111.1 '1111I111"II,I,lllIlllIlIjI"IIIIII/IlII/IIII/IIIIIIIII/IIIIIIIII,,1I11I1I1111111111111./11./111111.",,, II""! 1111111/,,1111'1, 11111 /1 I ,!II I '1 1"I/"I'i /111!1I1111 ,,,/,1,,, 1,1, I I I 
50 100 150 200 250 300 
High Resolution M/z 











7.5 7.0 6 .5 6 .0 5.5 5.0 4.5 4.0 3.5 




3.0 2.5 2.0 1.5 
16 

















11 , , I I I I 
~ 











150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 
8 Figure A2.3.6 13C NMR spectrum of 60 in CDCI31 400MHz 
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~ Figure A2.3.9 COSY spectrum of 60 in CDCI3, SOOMHz (The sample of 60 used for the COSY experiment was not as pure as the one 
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~ Figure A2.3.10 NOESY spectrum of 60 in CDCI3, SOOMHz. (The sample of 60 used for the NOESY spectrum was not as pure as the one 
used for the 10 NMR, however the impurities can easily be identified by comparing the lD and COSY spectra) 
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List of spectra: 
• HPLC profile 
• IR 
• lH NMR (400MHz, CDCI3) 
• 13C NMR (400MHz, CDCI3) 
• HSQC (400MHz, CDCI3) 
• COSY (400MHz, CDCI3) 
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A2.S Epoxide intermediate (1) 
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Epoxide intermediate (1) 
IUPAC [2-(1-Isopropyl-4b,8,8,-trimethyl-4b,5,6,7,8,8a,9,10-octahydro-
phenanthren-2-yloxymethyl-oxirane] 
List of spectra: 
• HREIMS 
• lH NMR (400MHz, CDCI3) 
• 13C NMR (400MHz, CDCh) 
• HSQC (300MHz, CDCh) 
• HMBC (300M Hz, CDCI3) 
• COSY (300MHz, CDCI3) 
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octahydro-phenanthren-2 -yloxy )-propan-2-01] 
List of spectra: 
• IR 
• HREIMS 
• lH NMR (400MHz, CDCh) 
• 13C NMR (400MHz, CDCI3) 
• HSQC (300M Hz, CDCh) 
• HMBC (300M Hz, CDCI3) 
• COSY (300M Hz, CDCh) 
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A2.7 Compound 3 
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phena nthren-2 -yloxy)-3-(7 -chloroquinolin-4-yl-piperazine )-l-yl-propa n-2 -01] 
List of spectra: 




• lH NMR (400MHz, CDCb) 
• 13C NMR (400MHz, CDCb) 
• HSQC (300M Hz, COCI3) 
• HMBC (300MHz, CDCb) 
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Figure A2.7.1 HPLC profile of compound 3 (H20: ACN) 
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Figure A2.7.2 UV absorbance of compound 3 (Rt=3.08) and the minor impurity (Rt=2.58) 
230 







































~ Figure A2.7.3 IR spectrum of compound 3 
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~ Figure A2.7.6 13C NMR spectrum of compound 3 in CDCI3( 400MHz 
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~ Figure A2.7.8 HMBC spectrum of compound 3 in CDCh, 300MHz 
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List of spectra: 
• IR 
• HREIMS 
• lH NMR (400MHz, CDCh) 
• 13C NrvlR (400MHz, CDCh) 
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List of spectra: 
• IR 
• HREIMS 
• lH NMR (400MHz, CDCI3) 
• 13c NMR (400MHz, CDCh) 
• HSQC (300M Hz, CDCI3) 
• HMBC (300MHz, CDCh) 
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~ Figure A2.9.3 lH NMR spectrum of compound 5 in CDCI31 400MHz 
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phenanthren-2-yloxy)-3-(2-ethoxyphenyl-pi perazine )-l-yl-propan-2-01] 
List of spectra: 
• IR 
• HREIMS 
• lH NMR (400MHz, CDCI3) 
• 13C NMR (400MHz, CDCb) 
• HSQC (300MHz, CDCI3) 
• HMBC (300MHz, CDCb) 
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~ Figure A2.10.2 HREIMS spectrum of compound 6 
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lH NMR spectrum of compound 6 in CDCI3f 400MHz 
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~ Figure A2.10.S HSQC spectrum of compound 6 in CDCl3 , 300MHz 
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~ Figure A2.10.6 HMBC spectrum of compound 6 in CDCI31 300MHz 
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IUPAC [(7-chloroquinolin-4-yl)- iperazine] 
List of spectra: 
• lH NMR (300MHz, COCI3) 
• 13C NMR (300M Hz, COCI3) 
• HSQC (300MHz, COCb) 
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~ Figure A2.11.1 lH NMR spectrum of amine 3 in CDCb, 300MHz 




8 5 3 
2 
4 7 4& 
160 150 140 130 120 110 100 
~ Figure A2.11.2 13C NMR spectrum of amine 3 in CDCI3, 300MHz 
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